Avzivi (bevacizumab-tnjn) / Bio-Thera Solutions, Cipla, BeOne Medicines, Biomm, Mega Lifesciences, Sandoz - LARVOL DELTA

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - P3 | N=408 | Recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial completion date: Jun 2034 ➔ Jun 2029

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) (ESMO 2023) - P2 | "No new safety signals were identified in either arm. The OS data are premature and need further follow-up."

Clinical • Metastases • P2 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • TIGIT

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov) - P2 | N=87 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2026 ➔ Jun 2027

Enrollment open • Platinum sensitive • Trial initiation date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov) - P3 | N=226 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Mar 2029 ➔ Mar 2034

Trial completion date • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • IL2

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Not yet recruiting | Sponsor: City of Hope Medical Center | Initiation date: Jul 2026 ➔ Oct 2026

Trial initiation date • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor • BRAF

A092001: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Mesothelioma • Oncology • Peritoneal Mesothelioma • Psoriatic Arthritis • Solid Tumor

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial (clinicaltrials.gov) - P=N/A | N=202 | Recruiting | Sponsor: Mayo Clinic | N=120 ➔ 202

Enrollment change • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=4 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=88 ➔ 4 | Trial completion date: Sep 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Jan 2026

Enrollment change • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Aug 2029 ➔ Feb 2031 | Trial primary completion date: Aug 2029 ➔ May 2030

Checkpoint inhibition • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - P3 | N=404 | Completed | Sponsor: BeOne Medicines | Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov) - P3 | N=4994 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Breast Cancer • Oncology • Solid Tumor • ER • HER-2

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2/3 | N=444 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Apr 2027

Platinum resistant • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - P2 | N=349 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • AKT1

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P3 | N=403 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Head and Neck Cancer • Hypopharyngeal Cancer • Lung Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Carcinoma of Unknown Primary • Tongue Carcinoma

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - P3 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=29 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. (PubMed, Cancer Immunol Immunother) - P2 | "In patients with advanced HCC, tislelizumab plus BAT1706 demonstrated promising ORR, while adding ociperlimab was not associated with improved efficacy. The safety profile of ociperlimab and tislelizumab plus BAT1706 was tolerable and manageable, with no new safety signals identified."

Clinical • Journal • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (ChiCTR) - P1 | N=230 | Recruiting | Sponsor: Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Institute); Sun Yat-sen University Cancer

First-in-human • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Prospective, single-arm, multicenter phase II clinical study of pamiparib combined with TC regimen and bevacizumab in neoadjuvant therapy for untreated advanced ovarian cancer (ChiCTR) - P2 | N=38 | Completed | Sponsor: Fujian Cancer Hospital; Fujian Cancer Hospital | Not yet recruiting ➔ Completed

Trial completion • Oncology • Ovarian Cancer • Solid Tumor

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Feb 2028 ➔ Aug 2029 | Trial primary completion date: Aug 2027 ➔ Aug 2029

Checkpoint inhibition • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (clinicaltrials.gov) - P2 | N=535 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2026 ➔ Apr 2026

Biomarker • Enrollment open • IO biomarker • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1